SHANDONG BOAN BIOTECH.H 1 Total Assets
SHANDONG BOAN BIOTECH.H 1 total assets. Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) holds total assets worth €4.13 Billion EUR (≈ $4.82 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SHANDONG BOAN BIOTECH.H 1 (UJ9) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of SHANDONG BOAN BIOTECH.H 1 (2021–2025)
Total assets of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025. This chart illustrates how SHANDONG BOAN BIOTECH.H 1's total assets have evolved over time, based on quarterly financial data. See SHANDONG BOAN BIOTECH.H 1 (UJ9) stock price for real-time trading data and today's change.
SHANDONG BOAN BIOTECH.H 1 - Asset Composition Analysis
SHANDONG BOAN BIOTECH.H 1 Total Assets Breakdown (December 2025)
SHANDONG BOAN BIOTECH.H 1 total assets breakdown as of December 2025. SHANDONG BOAN BIOTECH.H 1's total assets of €4.13 Billion consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.4% |
| Accounts Receivable | €646.52 Million | 15.7% |
| Inventory | €129.96 Million | 3.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.42 Billion | 34.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SHANDONG BOAN BIOTECH.H 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore UJ9 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SHANDONG BOAN BIOTECH.H 1's current assets represent 48.8% of total assets in 2025, an increase from 44.6% in 2021.
- Cash Position: Cash and equivalents constituted 27.4% of total assets in 2025, down from 29.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 26.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 34.5% of total assets.
SHANDONG BOAN BIOTECH.H 1 Competitors by Total Assets
Key competitors of SHANDONG BOAN BIOTECH.H 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
SHANDONG BOAN BIOTECH.H 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 1.47 | 1.35 |
| Quick Ratio | 2.18 | 1.21 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.15 Billion | €307.60 Million | €193.40 Million |
SHANDONG BOAN BIOTECH.H 1 - Advanced Valuation Insights
This section examines the relationship between SHANDONG BOAN BIOTECH.H 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 44.7% |
| Total Assets | €4.13 Billion |
| Market Capitalization | $244.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values SHANDONG BOAN BIOTECH.H 1's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SHANDONG BOAN BIOTECH.H 1's assets grew by 44.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SHANDONG BOAN BIOTECH.H 1 (2021–2025)
The table below shows the annual total assets of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
+44.69% |
| 2024-12-31 | €2.85 Billion ≈ $3.33 Billion |
+22.72% |
| 2023-12-31 | €2.32 Billion ≈ $2.72 Billion |
+5.49% |
| 2022-12-31 | €2.20 Billion ≈ $2.58 Billion |
+4.55% |
| 2021-12-31 | €2.11 Billion ≈ $2.46 Billion |
-- |
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more